Request Demo
Cellino Announces Partnership with Karis Bio to Develop First Nebula™-Powered Autologous iPSC Therapy for Cardiovascular Disease
15 Apr 2025
Cell TherapyClinical Study
CAMBRIDGE, Mass. & ATLANTA & SEOUL, South Korea--(BUSINESS WIRE)--Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalized regenerative medicine, today announced its expansion into the Asia-Pacific region through a strategic collaboration with Karis Bio, a leading South Korean cell therapy biotech. The partnership aims to industrialize the world’s first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy for peripheral artery disease (PAD) and coronary artery disease (CAD).
The collaboration is set to accelerate the development of Karis Bio’s innovative autologous iPSC-derived endothelial cell (iPSC-EC) therapy designed to generate new blood vessels in ischemic organs. Karis Bio’s first-in-human clinical study in South Korea leverages patient-specific iPSCs to restore blood flow and repair damaged tissues, offering patients a revolutionary alternative to conventional invasive procedures such as stents or bypass surgery, while eliminating the risk of immune rejection.
Cellino’s Nebula™ platform will enable scalable, high-quality production of autologous iPSCs, accelerating Karis Bio’s path to commercial scale. The Nebula™ platform is a closed-cassette, advanced biomanufacturing system that is both autonomous and deployable at the point of Karis Biouring robust, reproducible, and contamination-free production. The initial phase of the collaboration focuses on industrializing autologous iPSC manufacturing, with plans to expand into Phaseperipheral artery disease (PAD)A (hecoronary artery disease (CAD)e U.S.
“We are excited to partner with Karis Bio to pioneer the wKaris Biorst Nebula™-powered autologous iPSC therapy for peripheral artery disease,” said Nabiha Saklayen, Ph.D., CEO & Co-Founder of CellinoKaris Bioollaboration solidifies our commitment to forging powerful alliances with the world’s leading therapeutics innovators.”
Cellinoaugural first-in-human study using an autologous iPSC-derived therapy in South Korea is a pivotal adKaris Bio in regenerative medicine,” said Young-sup Yoon, M.D., Ph.D., CEO of Karis Bio. “This collaboration with Cellino will mutually leverage the strengths of both organizations, using Cellino’s Nebula™ platform and Karis Bio’s vessel regeneration technology to pave the way for the next generation of patient-specific cardiovascular disease therapies to be delivered worldwide.”Karis Bio
This collaboration marks CellinoKaris Bioral expansion into the Asia-Pacific region and underscores its global visiperipheral artery diseasel therapies widely accessible. By integrating AI-driCellinoomation, robotics, and high-throughput biomanufacturing, Cellino and Karis Bio are poised to accelerate the development of personalized regenerative medicines for patients with cardiovascular disease.
Cellino is a leader in adCellinobiomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. Learn more at www.cellinobio.com and follow us on LinkedIn and X.CellinoKaris Biocardiovascular disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!